临床荟萃 ›› 2023, Vol. 38 ›› Issue (12): 1140-1145.doi: 10.3969/j.issn.1004-583X.2023.12.015
李仁霞, 周泽平(
)
收稿日期:2023-10-17
出版日期:2023-12-20
发布日期:2024-01-30
通讯作者:
周泽平
E-mail:zhouzeping@outlook.com
Received:2023-10-17
Online:2023-12-20
Published:2024-01-30
摘要：
免疫性血小板减少症(ITP)是1种自身免疫性出血性疾病。血小板生成素受体激动剂(TPO-RA)是ITP的二线治疗药物,主要作用机制是通过刺激巨核细胞生成从而增加血小板生成。本文就TPO-RA在ITP中的作用机制、疗效、安全性,以及目前在临床中使用的问题等方面展开阐述,旨在总结TPO-RA在ITP中的使用情况,以期提高临床工作者对该类药物的认识。
中图分类号:
李仁霞, 周泽平. 血小板生成素受体激动剂在成人免疫性血小板减少症中的应用[J]. 临床荟萃, 2023, 38(12): 1140-1145.
| [1] |
Li J, Van d WDE, Zhu G, et al. Desialylation is a mechanism of fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia[J]. Nat Commun, 2015, 6:7737.
doi: 10.1038/ncomms8737 pmid: 26185093 |
| [2] |
Makar RS, Zhukov OS, Sahud MA, et al. Thrombopoietin levels in patients with disorders of platelet production: Diagnostic potential and utility in predicting response to TPO Receptor agonists[J]. Am J Hematol, 2013, 88(12):1041-1044.
doi: 10.1002/ajh.23562 pmid: 23913253 |
| [3] |
Yang L, Wang L, Zhao CH, et al. Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia[J]. Blood, 2010, 116(20):4307.
doi: 10.1182/blood-2010-02-267435 pmid: 20671119 |
| [4] |
Semple JW, Rebetz J, Maouia A, et al. An update on the pathophysiology of immune thrombocytopenia[J]. Curr Opin Hematol, 2020, 27(6):423-429.
doi: 10.1097/MOH.0000000000000612 pmid: 32868673 |
| [5] |
Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory itp: Difficulty in diagnosis and role of combination treatment[J]. Blood, 2019, 135(7): 472-490.
doi: 10.1182/blood.2019003599 URL |
| [6] |
Vianelli N, Auteri G, Buccisano F, et al. Refractory primary immune thrombocytopenia (ITP): Current clinical challenges and therapeutic perspectives[J]. Ann Hematol, 2022, 101(5):963-978.
doi: 10.1007/s00277-022-04786-y pmid: 35201417 |
| [7] |
Rodeghiero F. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP[J]. Br J Haematol, 2018, 181(2):183-195.
doi: 10.1111/bjh.2018.181.issue-2 URL |
| [8] |
Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia[J]. Blood, 2012, 119 (25): 5989-5995.
doi: 10.1182/blood-2011-11-393975 pmid: 22566601 |
| [9] |
Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia[J]. Blood Adv, 2019, 3(22):3780-3817.
doi: 10.1182/bloodadvances.2019000812 pmid: 31770441 |
| [10] | 侯明, 胡豫. 成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版)[J]. 中华血液学杂志, 2020, 41(8):617-623. |
| [11] |
Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists[J]. Int J Hematol, 2013, 98(1):10-23.
doi: 10.1007/s12185-013-1382-0 pmid: 23821332 |
| [12] |
Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (sb-497115), an oral, nonpeptide thrombopoietin receptor agonist[J]. Stem Cells, 2008, 27(2):424-430.
doi: 10.1634/stemcells.2008-0366 URL |
| [13] |
Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl[J]. Cytokine, 2004, 25(2):52-60.
pmid: 14693160 |
| [14] |
Ghanima W, Cooper N, Rodeghiero F, et al. Thrombopoietin receptor agonists: Ten years later[J]. Haematologica, 2019, 104(6):1112-1123.
doi: 10.3324/haematol.2018.212845 pmid: 31073079 |
| [15] |
Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome[J]. Blood, 2009, 114(18):3899-3908.
doi: 10.1182/blood-2009-04-219493 pmid: 19710504 |
| [16] |
Chen LY. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis[J]. Stem Cell Res, 2012, 9(2):77-86.
doi: 10.1016/j.scr.2012.05.001 pmid: 22683680 |
| [17] |
Di Buduo CA, Currao M, Pecci A, et al. Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation[J]. Haematologica, 2016, 101(12):1479-1488.
pmid: 27515246 |
| [18] |
Bao W, Bussel JB, Heck S, et al. Improved regulatory t-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents[J]. Blood, 2010, 116(22):4639-4645.
doi: 10.1182/blood-2010-04-281717 pmid: 20688957 |
| [19] |
Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)[J]. J Clin Med, 2017, 6(2):16.
doi: 10.3390/jcm6020016 URL |
| [20] | Liu XG, Liu S, Feng Q, et al. Thrombopoietin receptor agonists shift the balance of Fcγ receptors toward inhibitory receptor IIb on monocytes in ITP[J]. Blood, 2016, 128(6):852-861. |
| [21] |
Yang F, Zong H, Li F, et al. Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia[J]. Platelets, 2023, 34(1): 2135694.
doi: 10.1080/09537104.2022.2135694 URL |
| [22] |
Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial[J]. Lancet, 2015, 371(9610):395-403.
doi: 10.1016/S0140-6736(08)60203-2 URL |
| [23] |
Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia[J]. N Engl J Med, 2010, 363(20):1889-1899.
doi: 10.1056/NEJMoa1002625 URL |
| [24] |
Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment withromiplostim in thrombocytopenic patients with chronic ITP[J]. Blood, 2009, 113(10):2161-2171.
doi: 10.1182/blood-2008-04-150078 pmid: 18981291 |
| [25] |
Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: Safety and efficacy[J]. Br J Haematol, 2013, 161(03):411-423.
doi: 10.1111/bjh.2013.161.issue-3 URL |
| [26] |
Wang L, Gao Z, Chen XP, et al. Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and metaanalysis[J]. Sci Rep, 2016, 6(1): 39003.
doi: 10.1038/srep39003 |
| [27] |
Hayes S, Ouellet D, Zhang J, et al. Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing[J]. J Clin Pharmacol, 2013, 51(10):1403-1417.
doi: 10.1177/0091270010383019 URL |
| [28] |
Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomised, double-blind, placebo-controlled trial[J]. Lancet, 2009, 373(9664):641-648.
doi: 10.1016/S0140-6736(09)60402-5 pmid: 19231632 |
| [29] |
Gregory C. Eltrombopag for the treatment of immune thrombocytopenia[J]. Expert Rev Hematol, 2011, 4(3):261-269.
doi: 10.1586/ehm.11.25 pmid: 21671710 |
| [30] |
Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of longterm treatment of chronic/persistent ITP with eltrombopag: Final results of the EXTEND study[J]. Blood, 2017, 130(23):2527-2536.
doi: 10.1182/blood-2017-04-748707 URL |
| [31] |
Yang R, Li J, Jin J, et al. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia[J]. Br J Haematol, 2017, 176(01):101-110.
doi: 10.1111/bjh.2017.176.issue-1 URL |
| [32] |
Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia[J]. Blood, 2014, 123(25):3887-3894.
doi: 10.1182/blood-2013-07-514398 pmid: 24802775 |
| [33] |
Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia[J]. Br J Haematol, 2018, 183(3):479-490.
doi: 10.1111/bjh.2018.183.issue-3 URL |
| [34] |
Mei H, Zhou H, Hou M, et al. Avatrombopag for adult chronic primary immune thrombocytopenia: A randomized phase 3 trial in China[J]. Res Pract Thromb Haemost, 2023, 7(6):102158.
doi: 10.1016/j.rpth.2023.102158 URL |
| [35] |
Xie C, Zhao H, Bao X, et al. Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist[J]. J Cell Mol Med, 2018, 22(11):5367-5377.
doi: 10.1111/jcmm.13809 pmid: 30156363 |
| [36] |
Mei H, Liu X, Li Y, et al. A multicenter, randomized phase III trial of hetrombopag: A novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia[J]. J Hematol Oncol, 2021, 14(1):37.
doi: 10.1186/s13045-021-01047-9 |
| [37] |
Hidaka H, Kurosaki M, Tanaka H, et al. Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenia undergoing invasive procedures[J]. Clin Gastroenterol Hepatol, 2019, 17(6): 1192-1200.
doi: 10.1016/j.cgh.2018.11.047 URL |
| [38] |
Peck-Radosavljevic M, Simon K, Iacobellis A, et al. Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2)[J]. Hepatology, 2019, 70(4): 1336-1348.
doi: 10.1002/hep.30561 pmid: 30762895 |
| [39] |
Ding Z, Wu H, Zeng Y, et al. Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures[J]. Hepatol Int, 2023, 17(1): 180-189.
doi: 10.1007/s12072-022-10421-9 |
| [40] |
Ebbo M, Rivière E, Godeau B. Adult immune thrombocytopenia and thrombopoietin receptor agonist: Ten years later[J]. Rev Med Interne, 2021, 42(1): 38-45.
doi: 10.1016/j.revmed.2020.05.017 pmid: 32712041 |
| [41] |
Neunert CE. Thrombopoietin receptor agonist use for immune thrombocytopaenia[J]. Hamostaseologie, 2019, 39(3): 272-278.
doi: 10.1055/s-0038-1676129 pmid: 30646404 |
| [42] |
Kuter DJ, Mufti GJ, Bain BJ, et al. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim[J]. Blood, 2009, 114(18): 3748-3756.
doi: 10.1182/blood-2009-05-224766 pmid: 19671919 |
| [43] |
Ghanima W, Geyer JT, Lee CS, et al. Bone marrow fibrosis in 66 Immune Thrombocytopenia patients treated with thrombopoietin receptor agonists: a single center long-term follow-up[J]. Haematologica, 2014, 99(5): 937-944.
doi: 10.3324/haematol.2013.098921 pmid: 24463212 |
| [44] |
Brynes RK, Wong RS, Thein MM, et al. A 2-Year, Longitudinal, Prospective study of the effects of eltrombopag on bone marrow in patients with chronic immune thrombocytopenia[J]. Acta Haematol, 2017, 137(2):66-72.
doi: 10.1159/000452992 URL |
| [45] |
Janssens A, Rodeghiero F, Anderson D, et al. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia[J]. Ann Hematol, 2016, 95(7):1077-1087.
doi: 10.1007/s00277-016-2682-2 pmid: 27130310 |
| [46] |
Brynes RK, Orazi A, Theodore D, et al. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag:data from the EXTEND study[J]. Am J Hematol, 2015, 90(7):598-601.
doi: 10.1002/ajh.v90.7 URL |
| [47] |
Al-Samkari H, Kuter DJ. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia[J]. Am J Hematol, 2018, 93(12):1501-1508.
doi: 10.1002/ajh.25275 pmid: 30187942 |
| [48] |
Rodeghiero F. Is ITP a thrombophilic disorder?[J]. Am J Hematol, 2016, 91(1):39-45.
doi: 10.1002/ajh.24234 pmid: 26547507 |
| [49] |
Rottenstreich A, Kleinstern G, Spectre G, et al. Thromboembolic events following splenectomy: Risk factors, prevention, management and outcomes[J]. World J Surg, 2018, 42(3): 675-681.
doi: 10.1007/s00268-017-4185-2 pmid: 28808782 |
| [50] |
Weber E, Moulis G, Mahévas M, et al. Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study[J]. Rev Med Interne, 2017, 38(3): 167-175.
doi: S0248-8663(16)30555-0 pmid: 27793553 |
| [51] |
Rodeghiero F, Stasi R, Giagounidis A, et al. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: A pooled analysis of 13 clinical trials[J]. Eur J Haematol, 2013, 91(5):423-436.
doi: 10.1111/ejh.12181 pmid: 23927437 |
| [52] | Červinek L, Mayer J, Doubek M, et al. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults[J]. Doubek M, 2015, 102(1):7-11. |
| [53] |
Marshall AL, Scarpone R, De Greef M, et al. Remissions after long-term use of romiplostim for immune thrombocytopenia[J]. Haematologica, 2016, 101(12):e476-e478.
doi: 10.3324/haematol.2016.151886 URL |
| [54] |
Mazzucconi MG, Santoro C, Baldacci E, et al. TPO-RAs in pITP: Description of a case series and analysis of predictive factors for response[J]. Eur J Haematol, 2017, 98(3):242-249.
doi: 10.1111/ejh.12822 pmid: 27797414 |
| [55] |
Lozano ML, Mingot-Castellano ME, Perera MM, et al. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia[J]. Sci Rep, 2019, 9(1):16680.
doi: 10.1038/s41598-019-53209-y pmid: 31723222 |
| [56] |
Iino M, Sakamoto Y, Sato T. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice[J]. Int J Hematol, 2020, 112(2): 159-168.
doi: 10.1007/s12185-020-02893-y pmid: 32476083 |
| [57] |
Lucchini E, Palandri F, Volpetti S, et al. Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: Results of a phase II, multicentre, prospective study[J]. Br J Haematol, 2021, 193(2):386-396.
doi: 10.1111/bjh.v193.2 URL |
| [58] | Matzdorff A, Meyer O, Ostermann H, et al. Immune Thrombocytopenia-current diagnostics and therapy: Recommendations of a joint working group of DGHO, ÖGHO, SGH, GPOH, and DGTI[J]. Oncol Res Treat, 2018, 41(Suppl 5):1-30. |
| [59] |
Zaja F, Carpenedo M, Baratè C, et al. Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations[J]. Blood Rev, 2020, 41:100647.
doi: 10.1016/j.blre.2019.100647 URL |
| [60] |
Cuker A, Despotovic JM, Grace RF, et al. Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method[J]. Res Pract Thromb Haemost, 2021, 5(1): 69-80.
doi: 10.1002/rth2.12457 pmid: 33537531 |
| [61] |
Cooper N, Hill QA, Grainger J, et al. Tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: Results from a modified delphi panel[J]. Acta Haematol, 2021, 144(4):418-426.
doi: 10.1159/000510676 URL |
| [62] |
Roumier M, Le Burel S, Audia S, et al. High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia[J]. Am J Hematol, 2021, 96(2):E43-E46.
doi: 10.1002/ajh.26040 pmid: 33125750 |
| [1] | 王涛, 高玉伟, 王兴华, 胡秀红, 崔红蕊, 徐保振, 杨洪娟. 抗磷脂酶A2受体抗体与特发性膜性肾病的相关性[J]. 临床荟萃, 2023, 38(7): 606-612. |
| [2] | 陈瑾, 吕鸿雁, 刘晗, 刘建宁, 卢佳配, 张金巧. 靶向BCMA的嵌合抗原受体T细胞治疗三重难治性多发性骨髓瘤的研究进展[J]. 临床荟萃, 2023, 38(7): 654-658. |
| [3] | 裴红运, 文洁, 山凤莲. 结核病患者淋巴细胞程序性细胞死亡受体-1表达变化的研究进展[J]. 临床荟萃, 2023, 38(7): 659-662. |
| [4] | 杨金强, 张仁敏. 降钙素原与血小板比值评估发热伴血小板减少综合征预后的价值[J]. 临床荟萃, 2023, 38(4): 346-351. |
| [5] | 郭雨, 李永东. ARNI在高血压治疗中的研究进展[J]. 临床荟萃, 2023, 38(2): 181-184. |
| [6] | 陶嘉楠, 李文茜, 马秀雯, 安琪, 王学红. HER-2在肝细胞癌中表达及临床意义的meta分析[J]. 临床荟萃, 2023, 38(12): 1067-1072. |
| [7] | 黄小敏, 赵旭辉, 达德转, 马桃梅, 李红玲. EB病毒感染和程序性死亡受体配体1表达在晚期胃癌免疫靶向治疗中的研究进展[J]. 临床荟萃, 2023, 38(11): 1048-1052. |
| [8] | 胡文聪, 刘秀珍. 儿童抗MOG抗体合并抗NMDAR抗体双阳性自身免疫性脑炎2例并文献复习[J]. 临床荟萃, 2022, 37(8): 733-737. |
| [9] | 贾卓雅, 陈晓依, 陈树春. 胰高糖素样肽-1受体激动剂改善肥胖致雄性生殖功能下降的作用机制[J]. 临床荟萃, 2022, 37(7): 658-662. |
| [10] | 秦梅杰, 田茂露, 杨宇齐, 查艳, 袁静. 贝利尤单抗联合环孢素治疗难治性系统性红斑狼疮继发免疫性血小板减少1例并文献复习[J]. 临床荟萃, 2022, 37(6): 544-547. |
| [11] | 杨静静, 黄帅, 吴倩, 赵丽丽, 蒋影. 胰高血糖素样肽-1受体激动剂治疗肥胖的研究进展[J]. 临床荟萃, 2022, 37(5): 477-480. |
| [12] | 李青, 邓琦. 嵌合抗原受体T细胞治疗复发难治弥漫大B细胞淋巴瘤进展[J]. 临床荟萃, 2022, 37(2): 182-187. |
| [13] | 吕翠翠, 沈俊, 邓琦. 嵌合抗原受体巨噬细胞的研究进展[J]. 临床荟萃, 2022, 37(12): 1132-1136. |
| [14] | 李书凡, 王玉秀, 姜正华. T790M突变与TKI获得性耐药的晚期肺腺癌患者预后的相关性[J]. 临床荟萃, 2022, 37(11): 985-991. |
| [15] | 吴琼, 孙锋, 张凯, 王智怡, 张娜娜, 程慧, 向阳, 常晓慧. 艾曲泊帕联合小剂量泼尼松治疗老年难治复发原发免疫性血小板减少症疗效观察[J]. 临床荟萃, 2022, 37(11): 1008-1011. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
